ImmuCell Corporation (ICCC)
ImmuCell Corporation Return on Equity: -3.99%
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
ICCC Return on Equity Rankings
| Overall | 21st percentile | 3197 of 4055 |
| Sector | 47th percentile | 241 of 458 in Healthcare |
| Industry | 58th percentile | 7 of 17 in Diagnostic Substances |
ICCC Return on Equity Range, Past 5 Years
| Minimum | -5.90% | Mar 2009 |
| Maximum | 4.49% | Mar 2008 |
| Average | -2.18% |
About Return on Equity (ROE)
Click "Learn More" below to see how YCharts calculates Return on Equity.
Return on equity (ROE) measures the rate of return on the money invested by common stock owners and retained by the company thanks to previous profitable years. It demonstrates a company's ability to generate profits from shareholders' equity (also known as net assets or assets minus liabilities). In other words, ROE shows how well a company uses investment funds to generate growth. Return on equity is useful for comparing the profitability of companies within a sector or industry.
Investors generally are interested in company's that have high, increasing returns on equity.
Learn More
You may also be interested in these ICCC related companies
ICCC News
ImmuCell Announces Product Sales Growth and Other Financial Results for 2011
Feb 13, 8:01AM Benzinga
Feb 13, 8:01AM Benzinga
ImmuCell Presents Mast Out(R) Product Offering at World Animal Health Congress
Dec 08, 8:00AM Marketwire
Dec 08, 8:00AM Marketwire
ImmuCell Announces Product Sales Growth and Other Financial Results for Third Quarter of 2011
Nov 14, 8:00AM Marketwire
Nov 14, 8:00AM Marketwire
ImmuCell Announces Product Sales Growth and Other Financial Results for Second Quarter of 2011
Aug 15, 8:00AM Marketwire
Aug 15, 8:00AM Marketwire
=> $ICCC $6.97 Tomsche David Scott director P 1,873 @ $6.63 amnt $12,410 proc'd $641 7/12/2011
about 322 days ago by canarionyc
about 322 days ago by canarionyc
$ICCC is a thinster but worth keeping an eye on as it continues to hit new highs in a weak tape
about 342 days ago by sXc_Capital
about 342 days ago by sXc_Capital
NASDAQ 3 biggest advancers: $HOKU 38.32%, $ICCC 26.06%, $DSCO 22.52%, Fueled by NASDAQ Last Sale http://bit.ly/datajunkies
about 972 days ago by datajunkies
about 972 days ago by datajunkies
NASDAQ 3 biggest advancers: $HOKU 38.32%, $ICCC 26.06%, $DSCO 22.52%, Fueled by NASDAQ Last Sale http://bit.ly/datajunkies
about 972 days ago by datajunkies
about 972 days ago by datajunkies
NASDAQ 3 biggest advancers: $HOKU 38.32%, $ICCC 26.06%, $DSCO 22.52%, Fueled by NASDAQ Last Sale http://bit.ly/datajunkies
about 972 days ago by datajunkies
about 972 days ago by datajunkies
NASDAQ 3 biggest advancers: $HOKU 38.32%, $ICCC 26.06%, $DSCO 22.52%, Fueled by NASDAQ Last Sale http://bit.ly/datajunkies
about 972 days ago by datajunkies
about 972 days ago by datajunkies
NASDAQ 3 biggest advancers: $HOKU 85.22%, $ICCC 54.58%, $DSCO 34.23%, Fueled by NASDAQ Last Sale http://bit.ly/datajunkies
about 973 days ago by datajunkies
about 973 days ago by datajunkies
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| ICCC | 5.950 | -0.00 | -0.00% | 17.97M |
| ICB | 17.62 | -0.10 | -0.54% | |
| ICAD | 0.51 | +0.03 | +6.01% | 25.95M |
| ICA | 6.22 | +0.19 | +3.15% | 930.37M |
| IBOC | 18.67 | +0.17 | +0.92% | 1.245B |
| IBN | 30.14 | +0.85 | +2.92% | 16.88B |
| IBM | 196.55 | +2.25 | +1.16% | 225.13B |
| GTY | 16.26 | +0.05 | +0.31% | 541.25M |
| GTXI | 3.14 | +0.07 | +2.28% | 192.80M |
| GTU | 57.54 | -0.86 | -1.47% |
